These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16475699)

  • 1. Proliferation measurement in breast cancer by two different methods.
    Martínez-Arribas F; Martín-Garabato E; Lafuente P; Tejerina A; Lucas R; Sánchez J; Schneider J
    Anticancer Res; 2006; 26(1A):199-202. PubMed ID: 16475699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The S-phase fraction of the aneuploid cell subpopulation is the biologically relevant one in aneuploid breast cancers.
    Martinez-Arribas F; Nuñez-Villar MJ; Lucas AR; Sanchez J; Tejerina A; Schneider J
    Breast Cancer Res Treat; 2005 Jul; 92(1):77-80. PubMed ID: 15980994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flow cytometry vs. Ki67 labelling index in breast cancer: a prospective evaluation of 181 cases.
    Martínez-Arribas F; Núñez MJ; Piqueras V; Lucas AR; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2002; 22(1A):295-8. PubMed ID: 12017306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bcl-2 expression in breast cancer: a comparative study at the mRNA and protein level.
    Martínez-Arribas F; Alvarez T; Del Val G; Martín-Garabato E; Núñez-Villar MJ; Lucas R; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2007; 27(1A):219-22. PubMed ID: 17352236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
    Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness.
    Gasparini G; Pozza F; Meli S; Reitano M; Santini G; Bevilacqua P
    Anticancer Res; 1991; 11(6):2015-21. PubMed ID: 1776834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of proliferation activity in breast carcinoma by flow cytometry analysis of S-phase and quantitative analysis of MIB-1.
    Masood S; Bui MM; Lu L
    Ann Clin Lab Sci; 1998; 28(6):315-23. PubMed ID: 9846198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating hormone levels in breast cancer patients. correlation with serum tumor markers and the clinical and biological features of the tumors.
    Hernández L; Nuñez-Villarl MJ; Martínez-Arribas F; Pollán M; Schneider J
    Anticancer Res; 2005; 25(1B):451-4. PubMed ID: 15816610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bax expression in untreated breast cancer: an immunocytometric study of 255 cases.
    Martínez-Arribas F; Martín-Garabato E; Zapardiel I; Sánchez J; Lucas AR; Tejerina A; Schneider J
    Anticancer Res; 2008; 28(5A):2595-8. PubMed ID: 19035283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer.
    Järvinen TA; Kononen J; Pelto-Huikko M; Isola J
    Am J Pathol; 1996 Jun; 148(6):2073-82. PubMed ID: 8669491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.
    Leers MP; Hoop JG; van Beers M; van Rodijnen N; Pannebakker M; Nap M
    Cytometry B Clin Cytom; 2005 Mar; 64(1):43-52. PubMed ID: 15668953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast infiltrating ductal carcinoma: analysis of hormone, HER-2 receptors and Ki-67 proliferation marker.
    Mustać E; Zamolo G; Petković M; Dordević G; Radić J; Grgurević E; Batinac T
    Coll Antropol; 2008 Sep; 32(3):741-6. PubMed ID: 18982746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Male and female breast cancer--differences in DNA ploidy, p21 and p53 expression reinforce the possibility of distinct pathways of oncogenesis.
    André S; Pinto AE; Laranjeira C; Quaresma M; Soares J
    Pathobiology; 2007; 74(6):323-7. PubMed ID: 18087196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers.
    Crosier M; Scott D; Wilson RG; Griffiths CD; May FE; Westley BR
    Clin Cancer Res; 1999 Oct; 5(10):2682-8. PubMed ID: 10537329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression and intranuclear distribution of nucleolin in estrogen receptor-negative and estrogen receptor-positive breast cancers in women measured by laser scanning cytometry].
    Masiuk M
    Ann Acad Med Stetin; 2006; 52(2):23-32. PubMed ID: 17633394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of quantitative and semiquantitative methods of assessing MIB-1 with the S-phase fraction in breast carcinoma.
    MacGrogan G; Jollet I; Huet S; Sierankowski G; Picot V; Bonichon F; Coindre JM
    Mod Pathol; 1997 Aug; 10(8):769-76. PubMed ID: 9267818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases.
    Caly M; Genin P; Ghuzlan A A; Elie C; Fréneaux P; Klijanienko J; Rosty C; Sigal-Zafrani B; Vincent-Salomon A; Douggaz A; Zidane M; Sastre-Garau X
    Anticancer Res; 2004; 24(5B):3283-8. PubMed ID: 15510624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.